RIVA, the fully automated IV compounding system developed by ARxIUM, has been recognized as the highest performing IV robot by independent healthcare research firm KLAS. The rating was announced in its "Pharmacy 2016: Are You Partnered to Reduce Costs?" report, which surveyed hospital executives and pharmacy directors about value-based care initiatives and other topics.
RIVA's overall performance score of 85.9 was the highest for IV robots evaluated and scored more than 20 percent higher than its closest competitor. KLAS also reported that RIVA leads in accuracy and patient safety, and customers feel it is more reliable than the competition. In addition, RIVA was rated the top IV robot for improving staff productivity and minimizing medication spending.
"As decreasing reimbursements and global healthcare reform initiatives reshape capital expenditures, hospital administrators are looking for ways to reduce pharmacy costs," said Dr. Niels Erik Hansen, president and CEO of ARxIUM. "The latest KLAS report proves RIVA is meeting that need, while also increasing accuracy, patient safety and efficiency. Additionally, continued pharmacy recalls, heightened regulations and expensive medication outsourcing demonstrate the need for RIVA's unmatched technology."
RIVA is engineered with multiple safety technologies and prepares IV medications in an aseptic ISO Class 5 environment with laminar airflow. RIVA units have been installed worldwide and have cumulatively produced millions of IV doses safely and accurately. RIVA was recognized by KLAS as the Category Leader in "Pharmacy Automation: IV Robots" in its "2015 Best in KLAS: Medical Equipment & Infrastructure" report.
